The Quantellect read.As of Nov 19, 2026, 3 active firms cover Opko Health Inc: 2 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $1.50 to $4.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $2.75 sits 62% above the current $1.70. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 0 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.11 next quarter toward $-0.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy267%
Neutral133%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$2.75
+62.2% upside
Average target across 2 active firms as of Nov 19, 2026 vs $1.70 current
Highest Target$4.00
Average Target$2.75
Lowest Target$1.50
Detailed analyst forecasts for OPK
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 2 of 3 active firms rate OPK a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OPK EPS & revenue forecast
EPS · NEXT QUARTER
$-0.11
Range $-0.11 – $-0.11 · 1 analysts
Next period, 1 analysts expect Opko Health Inc to earn $-0.11 a share (range $-0.11 – $-0.11), versus — a year earlier. Full-year consensus is $-0.24, growing to $-0.34 the year after.
REVENUE · NEXT QUARTER
$80.3M
Range $59.3M – $135.8M · 1 analysts · -35% YoY
Revenue is expected to reach $80.3M (range $59.3M – $135.8M), -35.4% year-over-year. Full-year consensus is $420.7M, rising to $327.8M next year.
Top analysts covering Opko Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OPK.
#1
Brian Cheng
JP Morgan · Rank #87
Neutral
No targeton OPK
Overall win rate
51%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #350
Buy
$3.00+77.0% to target
Overall win rate
34%
+ Follow
#3
Michael Petusky
Barrington Research · Rank #452
Buy
No targeton OPK
Overall win rate
32%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$4.00+136.0% to target
Overall win rate
29%
+ Follow
#5
MR
Maury Raycroft
Jefferies
Neutral
$1.60-5.6% to target
Coverage
—
+ Follow
OPK stock forecast FAQ
What is OPK's average 12-month price target?+
The 2 active firms with a live target average $2.75 for Opko Health Inc over the next 12 months, ranging from a $4.00 high to a $1.50 low, as of Nov 19, 2026.
Is OPK stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OPK?+
The Street-high target is $4.00 (Piper Sandler), and the Street-low is $1.50. The average of all 2 active-firm targets is $2.75.
How many active Wall Street firms cover OPK?+
3 active firms have a recognized rating on Opko Health Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OPK?+
Among analysts who currently cover OPK, Brian Cheng of JP Morgan has the strongest overall Quantellect track record (Rank #87). Their current call is Neutral.
What is Opko Health Inc's projected EPS for next quarter?+
The consensus estimate is $-0.11 per share (range $-0.11 – $-0.11) across 1 analysts. Full-year EPS is projected at $-0.24, rising to $-0.34 the following year.
How much revenue is Opko Health Inc expected to report next quarter?+
Consensus revenue is $80.3M (range $59.3M – $135.8M). Full-year revenue is projected at $420.7M, growing to $327.8M next year.
Have analysts been upgrading or downgrading OPK lately?+
As of Nov 19, 2026, 2 of 3 active firms rate OPK a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OPK calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.